Ann: Invex Granted Type C Meeting with FDA, page-116

By my calculations, the FDA need to advise Invex of the WRO Type C advice in 75 days, which leads us to assume it's next week.

Nothing we can do but wait for the FDA to put the ASX out of its misery. The pessimism is contagious and is significantly dragging down sentiment and the price.

The only controllable that Invex does have is around the manufacturer appointment. I appreciate the delays due to COVID-19, but the appointment has been severely delayed to such an extent that one would worry that there is irreconcilable difficulties in the appointment of the manufacturer.

No drug = No trial.